Modality
Vaccine
MOA
FGFRi
Target
BCMA
Pathway
Incretin
NarcolepsyMDSWilms
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
Oct 2018
→ Aug 2031
Phase 1Current
NCT03952333
664 pts·MDS
2018-10→2031-08·Completed
664 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-235.4y awayPh2 Data· MDS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2031-08-23 · 5.4y away
MDS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03952333 | Phase 1/2 | MDS | Completed | 664 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA |